Cabaletta Bio (NASDAQ:CABA) Stock Gets Price Target Reduction from Citigroup

Cabaletta Bio (NASDAQ:CABA) had its price objective cut by Citigroup to $8.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Cabaletta Bio in a research note on Tuesday, September 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Cabaletta Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 7th. Wells Fargo & Company reduced their target price on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Friday, August 14th. Finally, William Blair raised shares of Cabaletta Bio to a “strong-buy” rating in a report on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.33.

Cabaletta Bio Price Performance

NASDAQ:CABA opened at $1.45 on Monday. The company has a market capitalization of $245.84 million, a PE ratio of -1.03 and a beta of 3.56. Cabaletta Bio has a 52-week low of $1.18 and a 52-week high of $4.23. The stock’s 50 day moving average price is $2.02 and its 200 day moving average price is $2.80.

Cabaletta Bio (NASDAQ:CABA) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, sell-side analysts anticipate that Cabaletta Bio will post -1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CABA. BlackRock Inc. acquired a new stake in shares of Cabaletta Bio during the second quarter worth $33,447,000. Opaleye Management Inc. grew its position in Cabaletta Bio by 180.0% in the 2nd quarter. Opaleye Management Inc. now owns 3,863,800 shares of the company’s stock valued at $12,016,000 after buying an additional 2,483,800 shares during the last quarter. Stonepine Capital Management LLC purchased a new position in Cabaletta Bio in the 2nd quarter valued at $2,852,181. Blue Owl Capital Holdings LP acquired a new position in Cabaletta Bio in the 2nd quarter valued at $2,223,000. Finally, GSA Capital Partners LLP acquired a new position in Cabaletta Bio in the 2nd quarter valued at $2,079,000.

Latest Cabaletta Bio News

Here’s some of the latest news about CABA:

• Positive Sentiment: HC Wainwright raised its EPS estimates across multiple periods, including FY2026 from a loss of $1.35 to $1.26 per share and FY2027 from $1.29 to $1.02 per share. The firm maintained its Buy rating and $16 target, a potentially supportive outlook, although Cabaletta is still expected to report losses.
• Positive Sentiment: Cabaletta presented new Phase 1/2 clinical data for rese-cel at ACR Convergence 2026. Further evidence on the experimental therapy could influence investor expectations, but the provided report does not detail the results. Article: Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data At ACR Convergence 2026
• Neutral Sentiment: A short-interest report says short interest totaled zero shares, despite describing a significant increase. The conflicting figures make it difficult to draw a reliable conclusion about bearish positioning.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for people with autoimmune diseases. The company’s approach aims to address disease-causing immune cells while limiting disruption to the broader immune system. Its lead program, CABA-201, is an investigational CD19-directed CAR T-cell therapy being studied across several autoimmune conditions. Cabaletta is also developing DSG3-CAART, an engineered cell therapy designed to target B cells that produce antibodies associated with pemphigus vulgaris.